Initial Research Sample Clauses

Initial Research. Initial Research ends with respect to a Compound, Compound by Compound, upon such time as the Joint Project Team selects such Compound for Phase I Clinical Study. Phases I and II Clinical Studies shall be conducted solely by Magainin, with assistance by Genentech or the Joint Project Team, as may be deemed necessary by the Joint Project Team, at Magainin's sole cost and expense, funding to be earmarked from funds generated by Genentech to Magainin under the then current tranche of Series A Preferred Stock pursuant to that certain Stock Purchase Agreement, dated of even date herewith. Phase III Clinical Studies and NDA/BLA filing shall be solely Genentech's obligation at Genentech's sole expense, the soleness of the expenses borne by Genentech being subject only to Magainin's opt-in for co-funding under Section 8.6 hereof.
Sample 1Sample 2
AutoNDA by SimpleDocs
Initial Research. Notwithstanding anything to the contrary in this Agreement, the initial purpose of the Collaboration Program for the Collaboration Target, [***], shall be the generation of a Collaboration Compound directed against [***] that meets the criteria set forth on Exhibit B (a “[***] Degrader”). Following the Second Amendment Effective Date, Company shall promptly prepare and provide to Vertex an initial Research Plan for [***]; provided that, notwithstanding the requirements of Research Plans as set forth in Section 2.3.1, such initial Research Plan for [***] shall be limited to a high-level description of the activities Company anticipates are reasonably necessary to generate a [***] Degrader within [***] months of the Second Amendment Effective Date rather than the activities to identify a Candidate Drug (such Research Plan, the “[***] Early Research Plan”). Vertex shall provide one or more Vertex Components for use in the Collaboration Program for [***]. Exhibit 10.12
Sample 1
Initial Research. The following tasks will be undertaken by the City of Portland. The goal of this task is to establish timing of infrastructure and development improvements.  Meet with property owners to determine development and financial goals, possible timing of development, phased approaches.  Clarify near term and long term transit and infrastructure improvements for 122nd Ave with TriMet, Portland Parks, and the Bureau of Environmental Services.  Develop a draft roadmap for the permit process, possible land use reviews and housing concepts.  Project Team meetings Milestone #1 Deliverable: draft roadmap for development/permit process; draft infrastructure and transit improvement timelines Task 2. Site Analysis, Development Program, Design Concepts: The following task will be jointly undertaken by the City of Portland and the Rossi/Xxxxxx/Xxxxx Family. The goal of this task is to develop baseline information about the sites, and conduct a market analysis.  Conduct appraisals and surveys for the development sites.  Market Study. Conduct a market study for the Rossi Farms and the Parkrose School District sites. The scope for the market study is to identify value, preferred uses, unit size, and anticipated rent rates.  Determine relationship of project to school capacity in the adjacent elementary, middle, and high schools.  Project Team meetings Milestone #2 Deliverable: appraisal report and surveys for the development sites, market study, school analysis
Sample 1

Related to Initial Research

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Subsequent Developments After the date of this Contract and until the Closing Date, Seller shall use best efforts to keep Buyer fully informed of all subsequent developments of which Seller has knowledge (“Subsequent Developments”) which would cause any of Seller’s representations or warranties contained in this Contract to be no longer accurate in any material respect.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

Time is Money Join Law Insider Premium to draft better contracts faster.